This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lind, M. J. Articles by Wilkinson, P. M. Search for Related Content PubMed PubMed Citation Articles by Lind, M. J. Articles by Wilkinson, P. M.

Comparative Pharmacokinetics and Alkylating Activity of Fractionated Intravenous and Oral Ifosfamide in Patients with Bronchogenic Carcinoma

CRC Department of Medical Oncology [M. J. L., T. C., N. T.], Department of Clinical Pharmacology [J. M. M., P. M. W.], Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, United Kingdom

20 patients with advanced non-small cell lung cancer were treated with ifosfamide and mesna 1.5 g/m² daily for 5 days; 10 received the drug by mouth and 10 i.v. Both schedules resulted in a reduction in the elimination half-life with an increased total and nonrenal clearance of ifosfamide over the 5-day period. Oral administration resulted in an unacceptably high incidence of encephalopathy(5/10) which was not seen in the i.v. group. In two patients this encephalopathy manifested itself as coma which lasted for 24 to 48 h but was fully reversible and in the other three cases as somnolence occurring for more than 50% of the patients' waking hours. Nadir blood counts and response rates were similar in both arms. The encephalopathy suggests that there are metabolic differences between the i.v. and oral routes and that a metabolite rather than the parent drug is responsible for this syndrome. In addition it was shown that the total and nonrenal clearance of the drug was significantly less when the drug was administered orally.

None of the pharmacokinetic parameters either singly or in combination predicted for ifosfamide toxicity. No correlation between the creatinine clearance and ifosfamide renal clearance was demonstrated suggesting tubular reabsorption of the drug. In conclusion, ifosfamide cannot be given orally at the conventionally employed i.v. doses.

¹ To whom requests for reprints should be addressed, at Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, M20 9BX, England.

Received 4/20/88. Revised 10/ 3/88. Accepted 10/26/88.

This article has been cited by other articles:

				P. N Patel Methylene Blue for Management of Ifosfamide-Induced Encephalopathy Ann. Pharmacother., February 1, 2006; 40(2): 299 - 303. [Abstract] [Full Text] [PDF]

				S. Donegan Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue Journal of Oncology Pharmacy Practice, January 1, 2001; 6(4): 153 - 165. [Abstract] [PDF]

				C. Aeschlimann, A. Küpfer, H. Schefer, and T. Cerny Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy Drug Metab. Dispos., September 1, 1998; 26(9): 883 - 890. [Abstract] [Full Text]